Latest news with #PBC
Forbes
a day ago
- Entertainment
- Forbes
Caleb Plant Vs. Armando Resendiz Results And Fight Card Results
Caleb Plant Caleb Plant and Jermall Charlo have their sights set on a grudge match later this year, but both men have to take care of business on Saturday night. Plant will face Armando Resendiz in the main event while Charlo faces Thomas LaManna in the co-main event at the Michelob Ultra Arena in Las Vegas. If you can't watch it live or you just want to follow along for my reactions, live scorecards for the featured fights and results from the prelim bouts, you're in the right space. The latest results and updates will appear below this paragraph. I'll score Plant-Resendiz and Charlo-LaManna. I'll deliver the results to the other fights on the card. LAS VEGAS, NV - SEPTEMBER 14: Caleb Plant (in green short) and Trevor McCumby (in black short) ... More exchange punches during their interim super middleweight world titles of the Premiere Boxing Championship on Saturday night at the T-Mobile Arena in Las Vegas, Nevada, United States on September 14, 2024. (Photo by Tayfun Coskun/Anadolu via Getty Images) September 14, 2024 – Win vs. Trevor McCumby March 25, 2023 – Loss vs. David Benavidez October 15, 2022 – Win vs. Anthony Dirrell November 6, 2021 – Loss vs. Canelo Álvarez January 30, 2021 – Win vs. Caleb Truax LAS VEGAS, NEVADA - NOVEMBER 25: Jermall Charlo (R) fights Jose Benavidez Jr. during their ... More middleweight bout at Michelob ULTRA Arena on November 25, 2023 in Las Vegas, Nevada. Charlo won by unanimous decision. (Photo by) November 25, 2023 – Win vs. Jose Benavidez Jr. June 19, 2021 – Win vs. Juan Macias Montiel September 26, 2020 – Win vs. Sergiy Derevyanchenko December 7, 2019 – Win vs. Dennis Hogan June 29, 2019 – Win vs. Brandon Adams
Forbes
2 days ago
- Entertainment
- Forbes
Caleb Plant Vs. Armando Resendiz Fight Card: What Time Does It Start?
LAS VEGAS, NEVADA - SEPTEMBER 13: Super middleweight boxer Caleb Plant poses on the scale during a ... More ceremonial weigh-in in Toshiba Plaza at T-Mobile Arena on September 13, 2024 in Las Vegas, Nevada. Plant is scheduled to fight Trevor McCumby for an interim WBA super middleweight title at the arena September 14. (Photo by) Caleb Plant vs. Armando Resendiz will headline a Premier Boxing Champions show on Prime Video on Saturday night from Las Vegas. On a pretty slow weekend for combat sports, the card has a chance to steal a piece of fight fans' attention. In case you're interested, here's how you can watch. In the co-main event, Jermall Charlo returns to the ring in search of a return to glory and relevancy. He takes on Thomas LaManna. If Plant and Charlo win their fights, the plan is for PBC to make a fight between the two later in the year. Plant and Charlo's beef stems from a backstage altercation in 2023 that saw the former slap the latter. It's crazy to think this moment is literally powering Saturday's event and potentially another show later in 2025, but apparently, that's the case. Here is a look at the complete card, which also features the next fight for rising lightweight star Curmel Moton. Moton is a protégé of Floyd Mayweather Jr. and supremely gifted. Still just 18, Moton has already amassed a 7-0 record as a professional with six KOs. LAS VEGAS, NEVADA - MARCH 21: Jordan Plant (L) interviews Curmel Moton during boxer workouts at the ... More Split T Boxing Club on March 21, 2024 in Las Vegas, Nevada. Moton will meet Anthony Cuba in a super featherweight bout on March 30, 2024, at T-Mobile Arena in Las Vegas. (Photo by) He should look impressive against Mastrapa, who will likely be in over his head. While I wouldn't expect Moton to be ready to be a serious title contender for at least two years, astute fans will likely want to get a glimpse of one of the sport's next potential superstars. Also on the undercard, undefeated super bantamweight KO artist Carl Jammes Martin takes on veteran Francisco Pedroza Portillo. Martin is from the Philippines, and his fighting style is all-action. The 'Wonder Boy' is just 26 years old and he has serious potential. If he can score an impressive win, he will put himself in a position to be one of Naoya Inoue's next challengers. With rumors swirling that Top Rank will land with Amazon Video, it makes the prospects of an Inoue-Martin fight all the more possible. Another intriguing fight is the clash between undefeated middleweight Yoenli Hernandez and Kyrone Davis. Hernandez is ranked in the Top 10 by every governing body besides the IBF. He is the No. 1 contender for Erislandy Lara's WBA title. Davis is only ranked by the IBF, as he is seventh in those rankings. If Hernandez can stay undefeated as a pro, he would likely land in the IBF's rankings, thereby creating more paths to a title shot against anyone wearing a title at 160 pounds. With all due respect to Janibek Alimkhanuly, the unified IBF and WBO champion, the current landscape of middleweight champions is arguably weaker than it has been in a long while. The division is hungry for a compelling star to emerge. We'll see if Hernandez can rise to become a household name. Be on the lookout for results following the event on Saturday.
Yahoo
3 days ago
- Business
- Yahoo
Jermall Charlo is having fun again, but big questions still surround his return to the ring
Jermall Charlo is saying all the right things ahead of his return to the ring Saturday against Thomas LaManna at the Michelob Ultra Arena in Las Vegas. 'I'm excited,' he told Uncrowned. He said he'd welcome a future fight against rival Caleb Plant, who boxes Jose Armando Resendiz in the main event of at the same show, and would fight Saul "Canelo" Alvarez if the opportunity presented itself too. He's even prepared to fight more frequently. Advertisement Charlo, a former two-weight world champion, is one of America's best-known boxers. He has an identical twin named Jermell, who is also a gifted fighter. Combined, they were a driving force for Premier Boxing Champions when the organization aired its events on Showtime Sports. Jermall, though, has been inactive. We've rarely seen him. He's only fought three times in the past five years. The sport of boxing has changed dramatically since he last held a title in 2021. His next bout will be his first on PBC's new broadcast partner, Prime Video, which is a partnership first announced at the end of 2023. There are numerous reasons for Charlo's absence. "When you can't stabilize your mind to think forward, that's where I was at. Not being able to explain it to anyone. Always shielded. I had to fight through my learning experience,' he said on PBC's YouTube channel regarding his struggles with mental health. He told the NY Post two years ago that he was 'dealing with all kinds of cases of [being] bipolar.' He said he turned his back on the world. His brother, Jermell, once said the reason he got the "Canelo" fight in 2023 instead of Jermall was because Jermall wasn't 'in the right mental state' to compete. Advertisement Jermall, though, faced his battles on his own terms, and got better at his own pace. Patience, he said, was key. Charlo's willingness to discuss his vulnerabilities so openly is important because a stigma remains attached to the condition. McLean Hospital, the largest psychiatric facility of Harvard Medical School, notes that only "25% of Black people seek mental health treatment when needed, compared to 40% of white people." Christine M. Crawford, MD, MPH, specializes in psychiatry, completed her fellowship at McLean, and said: 'African Americans silently live with mental health challenges for fear of being judged.' For Charlo, there was a period in his life when he 'didn't know what mental health even was.' Advertisement 'A lot of people shy away from showing that sensitive side of themselves," he said in 2023. "Because I'm the champ, they look at me like they expect greatness. And sometimes I don't have that greatness to provide. Then I'm not mentally focused. Now I'm mentally focused, I feel like I'm a better person.' After previous absences from the ring, Charlo has spoken of the need to 'rebuild himself' mentally. And that has never been more apparent than after speaking to him this month. He certainly seems rebuilt. I've been interviewing Charlo for six years. But after speaking to him in 2023, something seemed amiss. He looked vacant. His hair was dishevelled. He was uninterested. Never have I advised a fighter not to fight, but that was the one occasion I was close to penning a column saying his bout against Jose Benavidez Jr. should not go ahead. I even heard from a source close to Charlo that they shared a similar concern. Regardless, Charlo outpointed Benavidez by a 100-90 margin on one of the judges' scorecards. He won with ease. I didn't get to tell Charlo how wrong I was until this month, upon his return to the sport, after another extended spell away. Advertisement It was great to see him smile again. Talking to him in 2025 is like speaking to a different person. He's more engaged, and appears more content. "Having my brother [in camp helps], but on top of that, I rebuilt my team,' he said. This has energized him, he added, because he's now got 'a brotherhood' around him. 'We all believe in God. We're all strong, just knowing things come and go, I got rid of a lot of the drama. Got things out of my life that I won't get that back again. I feel a lot better. It's one of the best camps I had. There's laughter. Fun. It's not about material stuff no more.' Charlo's return to the sport comes at a pivotal time for American boxing considering the significant influence that Turki Alalshikh and Riyadh Season has. Whether Las Vegas' status as the Fight Capital of the World is under threat from Saudi Arabian finances remains to be seen. But Charlo has been watching with interest from afar. Advertisement His fire, he said, 'is lit.' He added: 'I can't wait to get in there and show the world. I've been waiting on management, promoters, team, to be right, mentally and physically, and give everybody what they want to see [against LaManna].' The biggest difference in the fight game from when Charlo was last the champ, to now, isn't just what Alalshikh brings to boxing, but also the presence of internet sensation Jake Paul. The sport 'is picking up.' Jermall Charlo was sensation in his most recent fight against Jose Benavidez Jr. () (David Becker via Getty Images) 'We're getting back to where we left off," Charlo said. "A lot of things have changed. It's a different era, we're going to the last part of the 2020s and it's a new generation of boxers, going from real-world champions, out of weight classes — which is crazy to me — getting to a point where Floyd [Mayweather] fought a big guy [Logan Paul], now it's going to YouTube, random rappers becoming boxers. You can be a painter, and as long as you can talk a little bit, it can be a pay-per-view bout. It's different.' Advertisement Though there are others, few have crossed over from the influencer scene as well as Paul, who has an 11-1 (7 KOs) pro record and has brought many of the world's best female fighters under one roof at Most Valuable Promotions — a firm he co-founded alongside former UFC executive Nikisa Bidarian. Paul returns June 28 against former champion Julio Cesar Chavez Jr. at a Golden Boy co-promoted show on DAZN. 'He was the first one to do it,' Charlo said of Paul, before remarking that other creators from YouTube are now 'over-saturating' the market and not respecting the sport. 'They haven't known how to put blood, sweat, and tears into it. That's when they're not taking boxing that serious.' Charlo wants to take the sport 'back to how it used to be,' he said. 'Boxing is not the same no more.' The sport in the U.S. would no doubt get a boost from a more active Charlo — one who is serious about boosting America's standing in the fight game. The biggest question that remains, though, is while he appears back to his old self outside of the ring, it's unclear, after another 18 months away, whether Charlo can still be his old self inside of it.
Yahoo
3 days ago
- Business
- Yahoo
Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?
Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant have gained 21.1% year to date against the industry's decline of 4.7%. The stock has outperformed the sector and the S&P 500 Index in this timeframe. Image Source: Zacks Investment Research Gilead Sciences is a dominant player in the HIV market with market-leading treatments. Its diverse portfolio also includes drugs for liver, hematology/oncology and inflammation/respiratory diseases. Approval of new drugs, encouraging pipeline progress and positive data readouts have boosted investors' sentiment in the past six months. However, the oncology business is under pressure. Let's delve into GILD's strengths and weaknesses to analyze how to play the stock at present. Gilead's flagship drug, Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg, BIC/FTC/TAF), for HIV-1 infection has become the number-one prescribed regimen for both treatment-naïve and switch patients. Biktarvy accounts for over 51% share of the treatment market in the United States and should maintain momentum for GILD in the upcoming quarters. Descovy (FTC 200 mg/TAF 25 mg) for pre-exposure prophylaxis (PrEP) is also witnessing good uptake. It maintains over 40% market share in the PrEP market in the United States. Gilead's efforts to innovate its HIV portfolio are impressive. Late-stage studies, PURPOSE 1 and PURPOSE 2, validated lenacapavir's potential to prevent HIV. The FDA accepted new drug application submissions for twice-yearly lenacapavir for HIV prevention under priority review, with a target action date of June 19, 2025. The European Medicines Agency validated the Marketing Authorization Application and EU-Medicines for All application for twice-yearly lenacapavir for HIV prevention. The successful development and potential approval of lenacapavir for the prevention of the disease should solidify Gilead's HIV franchise. Per GILD, lenacapavir, with its twice-yearly dosing, could set a new bar for HIV prevention and allow PrEP to reach a larger number of people who could benefit from a prevention regimen. The FDA approval of seladelpar for the treatment of primary biliary cholangitis (PBC) has strengthened GILD's liver disease portfolio and validated its CymaBay acquisition. The drug's initial uptake is encouraging. The candidate was approved under the brand name Livdelzi. Gilead also recently received conditional marketing authorization from the European Commission for seladelpar for the treatment of PBC. Gilead's oncology portfolio, comprising the Cell Therapy franchise and breast cancer drug Trodelvy, has diversified its overall business. However, the Cell Therapy franchise, comprising Yescarta and Tecartus, is currently under pressure due to competitive headwinds in the United States and Europe that are expected to continue in 2025. Breast cancer drug Trodelvy's sales were lower than expected in the first quarter due to inventory dynamics. Gilead announced positive top-line results from the phase III ASCENT-03 study on Trodelvy, which showed highly statistically significant and clinically meaningful improvement in progression-free survival in patients with first-line metastatic triple-negative breast cancer (mTNBC) who are not candidates for checkpoint inhibitors. The potential launch of anito-cel in multiple myeloma and Trodelvy in first-line mTNBC in 2026 will strengthen the company's oncology business. From a valuation standpoint, GILD is expensive. According to the price/earnings ratio, GILD's shares currently trade at 13.70x forward earnings, lower than the large-cap pharma industry's average of 14.62X but higher than its mean of Source: Zacks Investment Research Earnings estimates for GILD have moved north in the past 60 days. The bottom-line estimate for 2025 has increased to $7.91 from $7.87, while that for 2026 has improved to $8.39 from $8.31. Image Source: Zacks Investment Research Large biotech companies are generally considered safe havens for investors interested in this sector as they are well equipped to weather the uncertain macroenvironment. GILD is one of the dominant players in the HIV market. Gilead's efforts to constantly innovate its HIV portfolio should enable it to maintain growth amid competition from GSK plc GSK. GILD has also collaborated with Merck MRK to evaluate the investigational combination of islatravir and lenacapavir for the treatment of HIV. The potential launch of lenacapavir for PrEP in 2025 will be a significant boost for the company. Gilead's strategic deals and acquisitions to diversify its business are encouraging. However, Biktarvy sales are expected to be under pressure due to Medicare Part D redesign, which, in turn, should impact overall HIV growth. Hence, we advise prospective investors to wait and watch how well Biktarvy and the oncology business combat the existing headwinds before making a positive investment decision. In addition, we believe investors should also wait for better entry levels. For investors already owning the stock, it's important to note that Gilead has been consistently increasing and paying out dividends. The company declared a quarterly dividend of $0.79 per share of common stock for the second quarter of 2025. Its strong cash position (as of March 31, 2025, GILD had $7.9 billion of cash, cash equivalents and marketable debt securities) indicates that the current yield of 2.91% is sustainable. Gilead presently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Forbes
3 days ago
- Entertainment
- Forbes
Caleb Plant Vs. Armando Resendiz Fight Card Ring Walk Times
LAS VEGAS, NEVADA - SEPTEMBER 13: Super middleweight boxer Caleb Plant poses on the scale during a ... More ceremonial weigh-in in Toshiba Plaza at T-Mobile Arena on September 13, 2024 in Las Vegas, Nevada. Plant is scheduled to fight Trevor McCumby for an interim WBA super middleweight title at the arena September 14. (Photo by) Two consequential super middleweight boxing matchups headline Saturday's PBC Boxing card at Michelob Ultra Arena at Mandalay Bay. In those May 31 scraps, Caleb Plant puts his interim WBA super middleweight title on the line against Armando Resendiz, while former two-division champion Jermall Charlo meets Thomas LaManna. If Plant and Charlo leave Las Vegas with victories, there is a good chance they will face each other in their next fights. Below, we look at the ring walk times for the headlining fights on the Plant vs. Resendiz boxing card. Caleb Plant Vs. Armando Resendiz for Plant's interim WBA super middleweight title - 12 Rounds Jermall Charlo vs. Thomas LaManna - Super middleweight - 10 Rounds Yoenli Feliciano Hernandez vs. Kyrone Davis - Middleweight - 10 Rounds Isaac Lucero vs. Omar Valenzuela - Super welterweight - Eight Rounds Curmel Moton vs. Renny Viamonte Mastrapa - Lightweight - Eight Rounds Carl Martin vs. Francisco Pedroza Portillo - Super bantamweight - Eight Rounds Daniel Blancas vs. Kwame Ritter - Super middleweight - Eight Rounds Justin Cardona vs. Elijah Williams - Super lightweight - Six Rounds Cristian Cangelosi vs. Samuel Figueroa - Super welterweight - Six Rounds John Easter vs. Andres Martinez - Super middleweight - Six Rounds Brayan Gonzalez vs. Osiel Flores - Super bantamweight - Four Rounds Caleb Plant and Armando Resendiz are expected to make their ring walks at approximatley 11 p.m. ET Jermall Charlo and Thomas LaManna are expected to make their ring walks around 10 p.m. ET. Saturday, May 31, 2025 8:00 p.m. ET Michelob Ultra Arena at Mandalay Bay Resort and Casino Amazon Prime streaming LAS VEGAS, NEVADA - SEPTEMBER 14: Caleb Plant leaves the ring after his victory at T-Mobile Arena on ... More September 14, 2024 in Las Vegas, Nevada. (Photo by) Caleb Plant (23-2, 14 KOs) is the No. 3 ranked competitor in the super middleweight division, according to the latest ESPN rankings. The 32-year-old opened his career with a perfect 21-0 record, winning the IBF super middleweight crown in his 18th pro bout with a unanimous decision victory over José Uzcátegui. After three title defenses, Plant took a leap up in competition and faced Canelo Alvarez in a title unification contest. Alvarez scored an 11th-round TKO win in that contest. Plant bounced back from his first career defeat with a knockout win over Anthony Dirrell. Another loss followed as Plant dropped a decision to David Benavidez in March 2023 in a matchup for the interim WBC super middleweight belt. Plant returned to action in September 2024, capturing the vacant interim WBA super middleweight belt with a knockout win over Trevor McCumby. Armando Resendiz (15-2, 11 KOs) opened his career with 12 straight wins. Resendiz got knocked out by Elijah Garcia in 2023. His most recent outing was a fifth-round KO win over Fernando Paliza in February of this year. He is the No. 15 ranked competitor in the WBA rankings. LAS VEGAS, NEVADA - SEPTEMBER 14: Caleb Plant holds his daughter, Charly, after his technical ... More knockout win during a super middleweight bout at T-Mobile Arena on September 14, 2024 in Las Vegas, Nevada. (Photo by) 'He's tough, but tough ain't enough," Plant said of Resendiz. 'I'm gonna go in there and do what I do. He's gonna try his damnedest. But I'm gonna get the job done regardless. I'm gonna get my hand raised, and I plan on it being in fashion, but regardless of what happens, we're gonna hear the words and still,' LAS VEGAS, NEVADA - SEPTEMBER 30: Armando Resendiz of Mexico (red trunks) reacts after being ... More defeated by Elijah Garcia during the eighth round of their middleweight fight at T-Mobile Arena on September 30, 2023 in Las Vegas, Nevada. (Photo by) 'Plant is an amazing fighter, one of the elites at 168, but that motivates me even more. It makes me so happy because when you beat someone like that, it makes that win even bigger," said Resendiz. 'I believe in myself. I believe in the work I've done, and not only can I do all the same, but I can do even more. In the end, I know I can disarm Plant in the way that he can be disarmed. We're going to be ready for whatever comes my way during the fight,' added Resendiz. HOUSTON, TEXAS - JUNE 19: Jermall Charlo looks on prior to his WBC middleweight title fight against ... More and Juan Macias Montiel at Toyota Center on June 19, 2021 in Houston, Texas. (Photo by) A former two-division world champion (154 and 160 pounds), Jermall Charlo (33-0, 22 KOs) looks to make his mark at another weight class when he competes at 168 pounds in Vegas. The 35-year-old Charlo has not fought since late 2023 when he earned a decision over José Benavidez Jr. That win ended a break of more than two years for Charlo, who was stripped of his WBC title while he was inactive following a DWI arrest in May 2024. Thomas LaManna (39-5-1, 18 KOs) is riding a nine-fight winning streak heading into Saturday's event. The 33-year-old is looking for the biggest win of his career against Charlo. 'I'll be a fool to try to overlook him,' Charlo said of his opponent, Thomas LaManna. 'That's not what I'm doing. I'm Jermall Charlo. This is my legacy. This is my career. I'm putting it all on the line. Now I understand why Canelo and them, all the big names, GGG at the time I was at 160, I see why they would say, 'High risk, low reward.' But I'm not that saying towards LaManna in no type of combative way. I'm just saying, naturally, me beating him in fashion and doing what I do best, get out there and win the fight, I probably won't get the thumbs up and the likes from the fans. It's gonna be expected. 'If I go in there and make it a fight and make it tough and something crazy happens in the fight, then they'll be like, 'Oh, he's not Jermall Charlo no more.' So, the pressure is on me to be who I am. I'm not overlooking LaManna. He has some skill. He has experience, too. He just never been in there with anybody like me.' NEWARK, NEW JERSEY - DECEMBER 29: Thomas LaManna celebrates after defeating Nicolas Hernandez in ... More their middleweight fight at Prudential Center on December 29, 2023 in Newark, New Jersey. (Photo by) 'I learned from the Erislandy Lara fight that I can't let the moment get to me. If I can do that all throughout the week and get there to fight night, it's gonna be a long night for Charlo,' said LaManna. 'My whole mindset changed after the Lara fight. I didn't want to fight anymore. But when I came back, I knew I wanted to do it the right way. I knew this was my big opportunity at the biggest stage. Now I've got that great opportunity.' 'I definitely have the momentum over Charlo,' LaManna added. 'But we have to let the fights happen. We're gonna find out on May 31." Stay tuned for more on the Plant vs. Resendiz and Charlo vs. LaManna boxing fights.
